Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.
Understanding of inflammation in cancer indicates that cytokines are produced not only by immune cells, but also by cancer cells to evade immune responses, making cytokines promising oncology targets. Further, recent Phase II data for AbbVie’s lutikizumab has increased interest in Cantargia’s CAN10, as it blocks IL-33 and IL-36 in addition to IL-1.
Healthcare |
Flash note
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Update
Goran Forsberg
CEO
Forecast net debt (SEKm)
N/A
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 21.4 | (3.3) | (42.8) |
Relative | 25.1 | (9.1) | (48.7) |
52 week high/low | SEK6.2/SEK2.6 |
Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) in NSCLC and PDAC suggest that nadunolimab could have synergistic benefit with chemotherapy or ADCs, alleviating neuropathy and counteracting tumour promoting signals. Supportive clinical/biomarker data for PDAC was recently reported and the company is preparing for a Phase IIb trial in PDAC. Further, Cantargia shared positive interim data from TRIFOUR (Phase Ib portion), assessing nadunolimab in triple-negative breast cancer; the Phase II portion is ongoing. Cantargia also announced a $1.1m grant to support a new Phase Ib/IIa clinical trial for nadunolimab in leukaemia. A second programme, CAN10 (Phase I), is being developed for the treatment of autoimmune diseases. Encouraging data were shared in March 2024, highlighting the potential of CAN10 as a therapy in systemic sclerosis. At end-Q423, Cantargia had c SEK195m in cash and short-term investments.
Y/E Dec | Revenue (SEKm) | EBITDA (SEKm) | PBT (SEKm) | EPS (öre) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 0.0 | (377.9) | (371.8) | (290.43) | N/A | N/A |
2023A | 0.0 | (286.6) | (280.0) | (164.94) | N/A | N/A |
2024E | N/A | N/A | N/A | N/A | N/A | N/A |
2025E | N/A | N/A | N/A | N/A | N/A | N/A |